Biogen agrees to acquire neurological complaint specialist Reata Pharmaceuticals at 60 decoration

BioGen to Acquire Neurological complaint Specialist Reta Pharmaceuticals at a 60 Premium In its hunt for a deal that has been going on for months, BioGen( NASDAQ BIIB) has made a move on Friday. The biotech mammoth agreed to acquire Reta Pharmaceuticals,Inc.( NASDAQ RETA), a specialist in neurological conditions, for$172.50 per share or$7.3 billion. This … Read more